| This review discusses the clinical pharmacology of Cladribine Tablets in patients with relapsing multiple sclerosis, presenting pharmacokinetic, pharmacodynamic and pharmacometric data. |
| Cladribine Tablets are associated with a selective reduction in lymphocyte counts and durable efficacy relative to the fast disposition in plasma, and short-term treatment posology in each of the 2 treatment years. |
| The recommended cumulative dose of Cladribine Tablets 3.5 mg/kg over 2 years is shown to be appropriate in reducing relapse risk. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.